Pharmaceutical

Image

Global Primary Clostridioides Difficile Infection Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Oct 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Primary Clostridioides Difficile Infection Market – Industry Trends and Forecast to 2029

Market Size in USD Billion

CAGR - % Diagram

Diagram Forecast Period 2021–2029
Diagram Market Size (Base Year) USD 1.00 Billion
Diagram Market Size (Forecast Year) USD 1.63 Billion
Diagram CAGR %

Global Primary Clostridioides Difficile Infection Market, By Treatment (Medication, Surgery, Others), Route of Administration (Oral, Injectable, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Primary Clostridioides Difficile Infection Market Analysis and Size

The global primary clostridioides difficile infection market is expected to witness significant growth during the forecast period.  Clostridium difficile infection has significantly increased in recent years as many new strains have appeared and antimicrobial resistance has increased. It is one of the closely associated causes of antibiotic-related diarrhea, with symptoms such as pseudomembranous colitis, mild, self-limiting diarrhea to severe diarrhea, and life-threatening fulminant colitis, which typically results in death. COVID-19 also had a major impact on the market growth.

 Data Bridge Market Research analyses a growth rate in the global primary clostridioides difficile infection market in the forecast period 2022-2029. The expected CAGR of global primary clostridioides difficile infection market is tend to be around 6.30% in the mentioned forecast period. The market was valued at USD 1 billion in 2021, and it would grow upto USD 1.63 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Primary clostridioides difficile is a bacterial infection that can cause symptoms ranging from diarrhea to life-threatening colon inflammation. It has also evolved as a cause of community-associated diarrhea, ensuing in an increased prevalence of community-associated infection. Clinical illness ranges in severity from mild diarrhea to fulminant colitis and death.

Primary Clostridioides Difficile Infection Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Treatment (Medication, Surgery, Others), Route of Administration (Oral, Injectable, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

AstraZeneca (U.K.), Lilly (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), GSK plc (U.K.), Hikma Pharmaceuticals PLC (U.K.), Cipla Inc. (India), STI Pharma, LLC (U.S.)

Market Opportunities

  • Rising Drug Development Activities
  • Increasing Demand for Retail Pharmacies

Global Primary Clostridioides Difficile Infection Market Dynamics

Drivers

  • Rising Adoption of Antibiotics

Clostridium difficile infection is primarily associated with long-term antibiotic use. Increased antibiotic consumption changes the colon bacteria, allowing Clostridium difficile bacteria to grow. Antibiotics such as cephalosporins, clindamycin, and quinolones are more likely to cause Clostridium difficile infection (CDI). The higher use of these antibiotics is increasing the prevalence of clostridium difficile infection, which is most likely to boost the demand for its treatments. Therefore, the increasing consumption of antibiotics acts as a major driver of growth in the global primary clostridium difficile infection treatment market.

  • Growing Collaborations of Public-Private Organizations

With numerous small innovative players who are functioning in the market, there are several high-growth opportunities for major stakeholders to buy out companies so as to understand microbiomes with the aim of identifying new drugs and drug targets for multiple indications, such as liver disorders, diabetes, obesity, and metabolic disorders. Many market players are focusing on strategic collaborations and partnerships to increase their product pipelines with well-organized R&D techniques. Major companies have had numerous collaborations and partnerships in the last two years. Thus, all these partnerships are boosting the growth of the market.

Opportunities

  • Rising Drug Development Activities

Higher drug development activities for developing and launching several new drugs are projected to create market opportunities for growth in the market by providing doctors with an alternate treatment option. Additionally, the development of a new class of non-antibiotic drugs and vaccines is most likely to open up a large number of opportunities for major market players while also increasing the competition for manufacturing better treatment options. Therefore, increased drug development activities for developing novel drugs for better treatment and prevention are anticipated to create market growth in the near future.

  • Increasing Demand for Retail Pharmacies

The rise in the number of these infections therapeutics being delivered through retail pharmacies and the surge in the number of retail pharmacies in highly developed countries create much opportunities for the market growth. In addition, patients elect retail pharmacies to purchase drugs, as these are easily feasible.

 Restraints/Challenges

  • Lack of skilled professionals

The lack of trained who cannot treat the patients with appropriate treatments could limit the growth of the global primary clostridioides difficile infection market during a forecast period.

  • High Cost For Drug Development

The current treatment options that are available for CDIs are limited to antibiotics, and numerous pharmaceutical companies are presently focusing on developing non-antibiotic alternatives. The development of a new class of drugs will offer many growth opportunities for key players, but it will also essentially require major investments in R&D activities of novel therapies. The significantly high investment requirements may act as an obstacle to market growth.  

This global primary clostridioides difficile infection market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global primary clostridioides difficile infection market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Primary Clostridioides Difficile Infection Market       

COVID-19 has largely impacted and could continue to impact other companies' businesses, including their preclinical trials and clinical trials of microbiome-based therapeutics and diagnostic products. Although, with the relaxation of government restrictions associated with the pandemic and the occurrence of virtual clinical trials, R&D activities started their recovery since 2021.

Still, in the post-pandemic era, the biotechnology and pharmaceutical industries are expected to witness a huge growth in the future, as research and treatments are drifting towards normal patients again. Thus, this will significantly impact the global primary clostridioides difficile infection market.

Global Primary Clostridioides Difficile Infection Market Scope

The global primary clostridioides difficile infection market is segmented on the basis of treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

  • Medication
  • Surgery
  • Others

Route of Administration

  • Oral
  • Injectable
  • Others

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Primary Clostridioides Difficile Infection Market Regional Analysis/Insights

The global primary clostridioides difficile infection market is analysed and market size insights and trends are provided by treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global primary clostridioides difficile infection market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for global primary clostridioides difficile infection market throughout the forecasted period due to the presence of key manufacture of the product and increased prevalence of clostridioides difficile infection in this region.  

Asia-Pacific dominates the market due to increased prevalence of clostridioides difficile infection and increasing population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Primary Clostridioides Difficile Infection Market Share Analysis

The global primary clostridioides difficile infection market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global primary clostridioides difficile infection market.

Key players operating in the global primary clostridioides difficile infection market include:

  • AstraZeneca (U.K.)
  • Lilly (U.S.)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Sanofi (France)
  • Novartis AG (Switzerland)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Aurobindo Pharma (India)
  • Lupin (India)
  • Merck & Co., Inc. (U.S.)
  • Pfizer Inc. (U.S.)
  • GSK plc (U.K.)
  • Hikma Pharmaceuticals PLC (U.K.)
  • Cipla Inc. (India)
  • STI Pharma, LLC (U.S.)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The primary clostridioides difficile infection market was USD 1 billion in 2021.
The primary clostridioides difficile infection market is projected to grow at a CAGR of 6.30% during the forecast period of 2022-2029.
Asia-Pacific dominates the market due to the increased prevalence of clostridioides difficile infection and increasing population.
North America has been witnessing positive growth for primary clostridioides difficile infection market throughout the forecasted period due to the presence of key manufacturers of the product and the increased prevalence of clostridioides difficile infection in this region.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials